St. Louis pain practice publishes its own opioid numbers, reporting most patients weaned below 30 MME.
St. Louis, MO, United States — August 31, 2026
On International Overdose Awareness Day, an interventional pain physician argues the field’s failure was never only overprescribing — it was treating the prescription as the treatment.
Two narratives have dominated a decade of American pain medicine. In the first, physicians manufactured an overdose crisis by writing too many prescriptions. In the second, the correction overshot, and patients with real disease were tapered, discharged, and abandoned.
The Padda Institute Center for Interventional Pain Management is publishing its own internal figures on International Overdose Awareness Day because they sit in neither story.
- The average new patient has been in pain for more than 2.5 years and is receiving more than 90 morphine milligram equivalents (MME) per day.
- Within 90 days of active interventional treatment, 21% of patients are completely weaned off opioid pain medication, and within one year, 34% are completely weaned off all opioid pain medication.
- Of those who cannot be weaned, the vast majority are weaned below 30 MME per day — well beneath the thresholds at which federal prescribing guidance places its sharpest cautions.
About these numbers. These are practice-reported figures from our own patient population, not trial outcomes, and individual results vary. The arrival figure describes new patients; it is not a description of the established population, in which fewer than 1% remain above 90 MME.
What makes the numbers worth reporting is the mechanism. The practice is interventional first and does not offer medication-only pain management. When the pain generator is identified and treated directly — an inflamed facet joint, a compressed nerve root, an irritated sacroiliac joint — the clinical need for systemic opioids frequently falls on its own, without a taper imposed as an end in itself.
“Pain is the final pathway. It is the body screaming something has gone wrong. A prescription answers the report, but it may not answer the thing being reported.”
The distinction that matters
Tapering and treating are not the same intervention, though they are reported as though they were. A taper reduces a dose. Treating the generator changes why the dose was there.
Every injection and nerve procedure at the practice is performed under fluoroscopic or ultrasound guidance rather than by anatomical landmark, so placement is confirmed before medication is delivered. Diagnostic blocks establish which structure is producing pain before anything is treated — the difference between a knee that hurts and a knee that is the source of the hurt.
“Tapering is not a treatment. It is arithmetic. If you have not changed why the patient needed the medication, you have not treated anything — you have moved a number.”
The problem the drug creates
There is a second reason the mechanism matters, and it is one clinicians discuss more readily than the literature reports. Sustained opioid exposure can produce opioid-induced hyperalgesia — a state in which the nervous system becomes more sensitive to pain rather than less, through changes in NMDA receptor signaling and descending pain modulation. The clinical picture is a patient whose pain worsens as the dose rises, which is often misread as tolerance and answered with more medication.
Long-term opioid therapy also carries a metabolic cost that rarely appears in the overdose conversation: suppression of the hypothalamic-pituitary-gonadal axis, with consequent hypogonadism, and effects on insulin sensitivity, bone density and immune function. In a patient population already carrying a high burden of metabolic disease, that cost compounds.
The terrain underneath
The practice’s broader position is that chronic pain, opioid dependence and metabolic disease are three presentations of one inflammatory process rather than three epidemics.
Visceral adipose tissue is not inert storage. It is an endocrine organ that secretes interleukin-6, tumor necrosis factor alpha, and other cytokines directly into portal circulation. Those same mediators sensitize peripheral nociceptors and drive central sensitization in the dorsal horn. The result is a nervous system with a lower threshold for reporting pain — before any structural injury is considered.
Insulin resistance compounds it. Hyperglycemia impairs microvascular perfusion of peripheral nerve, and glycemic variability correlates with neuropathic pain intensity independently of average control. This is why the practice runs metabolic and lifestyle care alongside interventional treatment rather than after it.
“You can inject the right structure, in the right place, and watch it fail. Not because the procedure was wrong — because you put a repair into an inflamed body and expected the body to cooperate.”
About Padda Institute
The Padda Institute provides advanced interventional pain management, injury rehabilitation, post-concussion treatment, and metabolic health services in a comprehensive outpatient setting. Through a multidisciplinary approach, the Institute is committed to improving function, reducing pain, and helping patients return to productive, healthy lives.
Media contact
Dr. Gurpreet Singh Padda, MD, MBA, MHP
Padda Institute Center for Interventional Pain Management
4477 Woodson Rd, Suite 100, St. Louis, MO 63134
(314) 481-5000
This press release was distributed via EIN Presswire on August 31, 2026. View the original release.
If you are on opioid therapy and the dose keeps climbing
Padda Institute treats the structure producing the pain, so the medication requirement can fall on its own. We do not require you to come off opioids to be seen, and we do not taper anyone into withdrawal.
Or call (314) 481-5000 or text (314) 886-5902.
Msg & data rates may apply. Reply STOP to opt out, HELP for help. Text is not a secure channel — please don’t send medical or personal health information by text, and don’t use text for emergencies.
Dr. Gurpreet Singh Padda, MD, MBA, MHP
